Controlled drug delivery system based on ordered mesoporous silica matrices of captopril as angiotensin-converting enzyme inhibitor drug.

In the present study, captopril-loaded ordered mesoporous SBA-15 silica matrix were produced, functionalized, and characterized to obtain an efficient formulation of controlled drug delivery system. First, the starting SBA-15 materials are examined to verify that their synthesis has been successful considering the structural properties, using XRD, FTIR, and BET methods. Second, the influence of processing parameters of ordered mesoporous matrices for the loading and release of captopril was investigated. The release of captopril was controlled by tailoring the surface properties of the mesoporous silica via functionalization. The loading and release kinetics (in vitro in simulated gastric and intestinal fluids) showed that both of them were affected by the surface properties of the mesoporous silica materials. Such a formulation shows potential as an efficient controlled drug delivery system.

[1]  H. Askal.  New spectrophotometric methods for determination of captopril bulk drug and tablets. , 1991, Talanta.

[2]  Shichao Wang,et al.  Salicylidene Schiff Base Assembled with Mesoporous Silica SBA-15 as Hybrid Materials for Molecular Logic Function , 2007 .

[3]  K. Hidajat,et al.  Functionalized SBA-15 materials as carriers for controlled drug delivery: influence of surface properties on matrix-drug interactions. , 2005, Langmuir : the ACS journal of surfaces and colloids.

[4]  Evert Schepers,et al.  In vivo tissue response to resorbable silica xerogels as controlled-release materials. , 2005, Biomaterials.

[5]  N. Peppas,et al.  Mechanisms of solute release from porous hydrophilic polymers , 1983 .

[6]  J. Devoisselle,et al.  Inclusion of ibuprofen in mesoporous templated silica: drug loading and release property. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[7]  Jenny Andersson,et al.  Influences of Material Characteristics on Ibuprofen Drug Loading and Release Profiles from Ordered Micro- and Mesoporous Silica Matrices , 2004 .

[8]  Tad Hogg,et al.  Nanorobot architecture for medical target identification , 2008 .

[9]  F. Marmottini,et al.  Role of mesoporous silicates on carbamazepine dissolution rate enhancement , 2008 .

[10]  M. Vallet‐Regí,et al.  Mesoporous MCM-41 as Drug Host System , 2003 .

[11]  G. Giammona,et al.  Mesoporous silicate as matrix for drug delivery systems of non-steroidal antinflammatory drugs , 2002 .

[12]  Y. Sugahara,et al.  Adsorption of taxol into ordered mesoporous silicas with various pore diameters , 1999 .

[13]  Chi H. Lee,et al.  Drug delivery systems for hormone therapy. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[14]  M. Vallet‐Regí.  Ordered Mesoporous Materials in the Context of Drug Delivery Systems and Bone Tissue Engineering , 2006 .

[15]  T. Bein,et al.  Tuning drug uptake and release rates through different morphologies and pore diameters of confined mesoporous silica , 2009 .

[16]  Frederick E. Petry,et al.  Principles and Applications , 1997 .

[17]  Lawrence X. Yu,et al.  A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. , 2006, Molecular pharmaceutics.

[18]  Fredrickson,et al.  Triblock copolymer syntheses of mesoporous silica with periodic 50 to 300 angstrom pores , 1998, Science.

[19]  M. Vallet‐Regí,et al.  Mesoporous SBA-15 HPLC evaluation for controlled gentamicin drug delivery. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[20]  M. Vallet‐Regí,et al.  Bioceramics and pharmaceuticals: A remarkable synergy , 2007 .

[21]  M. Vallet‐Regí,et al.  MCM-41 Organic Modification as Drug Delivery Rate Regulator , 2003 .

[22]  M. Ondetti,et al.  History of the Design of Captopril and Related Inhibitors of Angiotensin Converting Enzyme , 1991, Hypertension.

[23]  N. Peppas,et al.  A SIMPLE EQUATION FOR SOLUTE RELEASE PART 1. FICKIAN AND NONFICKIAN RELEASE FROM NONSWELLABLE DEVICES IN THE FORM OF SLABS, SPHERES, CYLINDERS OR DISKS , 1987 .

[24]  Matthias Epple,et al.  Inorganic nanoparticles as carriers of nucleic acids into cells. , 2008, Angewandte Chemie.

[25]  N. Peppas.  Analysis of Fickian and non-Fickian drug release from polymers. , 1985, Pharmaceutica acta Helvetiae.

[26]  María Vallet-Regí,et al.  Mesoporous Materials for Drug Delivery , 2008 .

[27]  Shilun Qiu,et al.  Controlled release of Captopril by regulating the pore size and morphology of ordered mesoporous silica , 2006 .

[28]  R. Langer,et al.  Drug delivery and targeting. , 1998, Nature.

[29]  N. Sultana,et al.  In vitro interactions of captopril with NSAID's. , 2006, Pakistan journal of pharmaceutical sciences.

[30]  V. Ramaswamy,et al.  Structural features of Penicillin acylase adsorption on APTES functionalized SBA-15 , 2008 .

[31]  M. Vallet‐Regí,et al.  Influence of pore size of MCM-41 matrices on drug delivery rate , 2004 .

[32]  Patrick Marroum,et al.  Mechanistic analysis of solute transport in an in vitro physiological two‐phase dissolution apparatus , 2012 .

[33]  Daliang Zhang,et al.  Drug Self-Templated Synthesis of Ibuprofen/Mesoporous Silica for Sustained Release , 2006 .

[34]  C Rossi,et al.  Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[35]  C. Brinker,et al.  Aerosol-assisted self-assembly of single-crystal core/nanoporous shell particles as model controlled release capsules. , 2006, Journal of the American Chemical Society.

[36]  P. Ashok,et al.  Design and statistical optimization of glipizide loaded lipospheres using response surface methodology , 2007, Acta pharmaceutica.